The pricing math on tradipitant tells you more about Vanda’s commercial strategy than any launch announcement could. At $255 per dose through standard pharmacy channels and $85 through a proprietary direct-to-consumer portal at nereus.us, the company has built a three-to-one price spread between its own platform and traditional retail — a structure that explicitly rewards bypassing the pharmacy benefit and, not coincidentally, bypassing the payer entirely. For a drug targeting a condition affecting an estimated 65 to 78 million American adults, that cash-pay positioning is a deliberate bet that motion sickness remains too episodic and too stigmatized for insurers to engage with seriously, at least in the near term.
The clinical foundation is real. Two Phase 3 trials — Motion Syros and Motion Serifos — were conducted under actual sea-travel conditions, not in laboratory tilt-chairs or rotating drum simulators. That design choice matters: regulatory reviewers saw vomiting prevention data generated in genuine vestibular chaos, which makes the efficacy signal harder to dismiss as an artifact of controlled provocation. Tradipitant’s mechanism as a selective NK-1 receptor antagonist targeting substance P is the same pathway exploited by aprepitant in chemotherapy-induced nausea, but applied to a sensory-mismatch cascade rather than chemoreceptor trigger zone stimulation. The FDA approved it December 30, 2025 — the first new pharmacologic option for motion sickness in over four decades, since scopolamine patches arrived in 1979.
What the press release buries, but the prescribing information surfaces, is the sedation liability. Tradipitant impairs driving and heavy-machinery operation, interacts with strong CYP3A4 inhibitors, and is contraindicated in hepatic impairment. For a drug taken an hour before car, plane, or boat travel, the drowsiness warning creates a counseling problem that physicians and pharmacists will need to navigate carefully — especially compared to the older antihistamine options patients already self-select without any prescription barrier. That friction could blunt uptake among the very population most likely to treat motion sickness as a minor inconvenience rather than a condition worth a clinic visit.
The one number worth tracking in the next two quarters is the direct-to-consumer prescription capture rate at nereus.us versus retail fill volume — that ratio will reveal whether Vanda’s vertical distribution model actually converts at scale or collapses under the weight of patient inertia and prescriber unfamiliarity.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
